Vigil Neuroscience Inc
Company Profile
Business description
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.
Contact
100 Forge Road
Suite 700
WatertownMA02472
USAT: +1 857 254-4445
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
66
Stocks News & Analysis
stocks
Best and worst performing ASX sectors of 2024
stocks
2 ASX companies with the traits of a long-term winner
video
Our outlook for 2025
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,420.50 | 75.50 | -0.89% |
| CAC 40 | 7,380.74 | 67.18 | 0.92% |
| DAX 40 | 19,909.14 | 75.18 | -0.38% |
| Dow JONES (US) | 42,544.22 | 29.51 | -0.07% |
| FTSE 100 | 8,173.02 | 52.01 | 0.64% |
| HKSE | 20,059.95 | 18.53 | 0.09% |
| NASDAQ | 19,310.79 | 175.99 | -0.90% |
| Nikkei 225 | 39,894.54 | 386.62 | -0.96% |
| NZX 50 Index | 13,110.74 | 159.27 | -1.20% |
| S&P 500 | 5,881.63 | 25.31 | -0.43% |
| S&P/ASX 200 | 8,159.10 | 75.90 | -0.92% |
| SSE Composite Index | 3,351.76 | 55.56 | -1.63% |